Literature DB >> 23377667

Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice.

Shuang Wei1, Martin U Egenti, Seagal Teitz-Tennenbaum, Weiping Zou, Alfred E Chang.   

Abstract

In this study, we used a murine D5 melanoma model to study the effects of local tumor irradiation on the therapeutic efficacy of adoptive T-cell therapy. Tumor irradiation was delivered in 5 daily fractions (8.5 Gy) to subcutaneous tumors on days 7-11 after tumor inoculation. After the last radiation dose, activated tumor-draining lymph node cells were transferred intravenously followed by intraperitoneal IL-2 administration. Tumor irradiation alone had no significant effect on tumor growth; however, it synergistically enhanced the therapeutic efficacy of T-cell therapy. For 2 days after tumor irradiation there was a significant reduction in T cells, B cells, and CD11c(+) dendritic cells in both the tumor microenvironment and the systemic lymphoid compartments. By days 4-6 after irradiation, the relative reduction in the number of Treg cells within the tumor and the systemic compartments was greater than the reduction in conventional T cells. Furthermore, the suppressive function of the Tregs was significantly impaired in irradiated versus untreated mice. Using effector T cells derived from congenic mice, we found that local tumor irradiation resulted in increased proliferation of donor T cells within the tumor and the systemic lymphoid compartments. Radiation was associated with increased expression of the effector cytokines IFN-γ and TNF-α by donor and host CD4(+) and CD8(+) T cells. Altogether, our data indicate that local tumor irradiation has a distinct modulatory effect on Tregs and can enhance systemic antitumor immunity associated with adoptive T-cell therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23377667      PMCID: PMC3607501          DOI: 10.1097/CJI.0b013e31828298e6

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  39 in total

1.  The effect of radiation therapy on lymphocyte subpopulations in cancer patients.

Authors:  M Raben; N Walach; U Galili; M Schlesinger
Journal:  Cancer       Date:  1976-03       Impact factor: 6.860

2.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

3.  Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.

Authors:  Fumito Ito; Abbey Carr; Hakan Svensson; Jiyun Yu; Alfred E Chang; Qiao Li
Journal:  J Immunother       Date:  2003 May-Jun       Impact factor: 4.456

4.  Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor.

Authors:  A E Chang; Q Li; D K Bishop; D P Normolle; B D Redman; B J Nickoloff
Journal:  Hum Gene Ther       Date:  2000-04-10       Impact factor: 5.695

5.  Effect of radiation therapy and in vitro x-ray exposure on lymphocyte subpopulations and their functions.

Authors:  J Wasserman; H Blomgren; B Petrini; E Baral; L E Strender; C Jarstrand; L V von Stedingk
Journal:  Am J Clin Oncol       Date:  1982-04       Impact factor: 2.339

6.  Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.

Authors:  Alfred E Chang; Qiao Li; Guihua Jiang; Donna M Sayre; Thomas M Braun; Bruce G Redman
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

7.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

8.  Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.

Authors:  Mala Chakraborty; Scott I Abrams; C Norman Coleman; Kevin Camphausen; Jeffrey Schlom; James W Hodge
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

10.  Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.

Authors:  Mala Chakraborty; Scott I Abrams; Kevin Camphausen; Kebin Liu; Tamalee Scott; C Norman Coleman; James W Hodge
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

View more
  19 in total

Review 1.  Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors:  Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

Review 2.  Immune checkpoint inhibitors: a new frontier in bladder cancer.

Authors:  Max Kates; Nikolai A Sopko; Hotaka Matsui; Charles G Drake; Noah M Hahn; Trinity J Bivalacqua
Journal:  World J Urol       Date:  2015-10-20       Impact factor: 4.226

Review 3.  Immunomodulatory effects of radiation: what is next for cancer therapy?

Authors:  Anita Kumari; Samantha S Simon; Tomika D Moody; Charlie Garnett-Benson
Journal:  Future Oncol       Date:  2015-12-01       Impact factor: 3.404

Review 4.  Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.

Authors:  Tae Kon Kim; Esten N Vandsemb; Roy S Herbst; Lieping Chen
Journal:  Nat Rev Drug Discov       Date:  2022-06-14       Impact factor: 112.288

Review 5.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

Review 6.  Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications.

Authors:  Shu Liu; Xiangdong Sun; Jinhua Luo; Hongcheng Zhu; Xi Yang; Qing Guo; Yaqi Song; Xinchen Sun
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

7.  Immunotherapy for malignant glioma.

Authors:  Carter M Suryadevara; Terence Verla; Luis Sanchez-Perez; Elizabeth A Reap; Bryan D Choi; Peter E Fecci; John H Sampson
Journal:  Surg Neurol Int       Date:  2015-02-13

8.  Effects of yak-activated protein on hematopoiesis and related cytokines in radiation-induced injury in mice.

Authors:  Yabin Duan; Xingchen Yao; Junbo Zhu; Yongping Li; Juanling Zhang; Xuejiao Zhou; Yijie Qiao; Meng Yang; Xiangyang Li
Journal:  Exp Ther Med       Date:  2017-10-03       Impact factor: 2.447

Review 9.  Radiotherapy and the tumor stroma: the importance of dose and fractionation.

Authors:  Turid Hellevik; Iñigo Martinez-Zubiaurre
Journal:  Front Oncol       Date:  2014-01-21       Impact factor: 6.244

10.  Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma model.

Authors:  Joanne Yh Lim; Dirk G Brockstedt; Edith M Lord; Scott A Gerber
Journal:  Oncoimmunology       Date:  2014-06-03       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.